• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Early Choroidal Changes Predict Myopia Progression but May Not Show Treatment Benefit

by
November 17, 2026
in Health
Reading Time: 4 mins read
0
Early Choroidal Changes Predict Myopia Progression but May Not Show Treatment Benefit

Early Choroidal Changes Predict Myopia Progression but May Not Show Treatment Benefit

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Early changes in choroidal vascular structure can predict long-term refractive progression in children receiving low-dose atropine, yet this predictive capacity does not automatically identify the specific therapeutic benefit attributable to the medication itself. In an analysis examining recent findings from the AMIXT randomized trial, researcher Jing Chen evaluated how four-month alterations in perifoveal luminal volume correlate with two-year refractive outcomes. The original investigation by Zuo and colleagues demonstrated that early three-dimensional choroidal vascular remodeling serves as a measurable indicator of subsequent myopic progression during daily treatment with 0.01 percent atropine. While these vascular metrics provide valuable clinical insights, interpreting what these structural shifts mean requires distinguishing between a patient’s natural ocular growth trajectory and their genuine biological response to pharmacologic intervention.

The investigated clinical cohort comprised children diagnosed with both myopia and intermittent exotropia who underwent three-dimensional choroidal imaging during the AMIXT clinical trial. By tracking volumetric adjustments in the choroid over time, researchers identified four-month changes in perifoveal luminal volume, designated as ΔLV₃, as a meaningful predictor of refractive progression at twenty-four months. Alongside these imaging observations, accompanying experimental studies revealed that choroidal endothelial oxidative stress and nitric oxide signaling pathways participate in this process. These laboratory findings offer biological plausibility for the role of vascular tissue in eye growth regulation, suggesting that the vascular layer actively responds during myopia management rather than acting as a passive tissue layer.

Despite the predictive accuracy of the ΔLV₃ vascular metric, prediction models categorize clinical outcomes based on observed rates of refractive change rather than comparative drug efficacy. Children who display slower refractive progression while using 0.01 percent atropine might possess an inherently favorable growth trajectory, a robust physiological response to the medication, or a combination of both factors. Conversely, continued refractive progression in a treated child does not inherently demonstrate a failure of drug benefit, as that individual might have experienced substantially faster myopic worsening without any therapeutic intervention. Consequently, an early choroidal metric may successfully pinpoint individuals who remain at risk of rapid progression without identifying which patients derive the least pharmacological benefit from atropine.

Broader randomized clinical trial data provide essential context for understanding how choroidal thickness changes relate to both natural ocular expansion and pharmacological responses. In the MOSAIC trial, greater choroidal thickening was associated with reduced axial elongation and slower refractive progression among children in both the atropine-treated groups and the placebo control groups. Furthermore, formal mediation analyses within that trial indicated that the overall effect of atropine on choroidal thickening was only partly explained by alterations in axial length or refractive error. These comparative patterns confirm that choroidal modifications capture dual signals, reflecting both the general trajectory of childhood eye enlargement and medication-specific biological adaptations.

Additional evidence from the LAMP trial reinforces this complex relationship across varying drug concentrations. Investigators in that trial documented concentration-dependent choroidal thickening that accompanied slower overall myopia progression, with statistical mediation analysis supporting a partial contribution of choroidal changes to the overall treatment effect observed at 0.05 percent atropine. Although two-dimensional measurements of choroidal thickness are not directly interchangeable with volumetric three-dimensional luminal volume assessments, both lines of investigation demonstrate that choroidal remodeling reflects both drug-induced responses and underlying developmental eye growth. These shared observations highlight the need for careful statistical and physiological differentiation when evaluating choroidal imaging biomarkers in pediatric populations.

Mediation analyses in the study by Zuo and collaborators identified statistically significant indirect effects operating through twenty-four-month choroidal volume changes, while cellular assays demonstrated the involvement of endothelial oxidative stress and nitric oxide pathways. Together, these complementary findings support the concept that the choroid serves as an active cellular participant during atropine-mediated myopia control. However, establishing biological plausibility and long-term volume mediation does not resolve the clinical interpretation of the earlier four-month ΔLV₃ measurement. Demonstrating that an early metric predicts subsequent refractive progression during an active treatment regimen does not prove that it can distinguish variations in the true treatment benefit generated by atropine.

For translation into routine ophthalmic practice, perifoveal luminal volume measurements may eventually help clinicians identify pediatric patients at elevated risk of continuing refractive progression, provided the predictive validity of ΔLV₃ receives independent clinical confirmation. Clinical specialists must exercise caution, as a small early increase in luminal volume should not automatically be interpreted as medication failure, especially when axial elongation and refractive progression remain the definitive outcomes of clinical concern. Moving forward, clinical investigations must evaluate whether early choroidal monitoring can differentiate between children who should remain on 0.01 percent atropine and those who require higher drug concentrations or supplementary interventions to achieve effective myopia control.

Subject of Research: Choroidal vascular remodeling and outcome prediction in childhood myopia atropine therapy

Article Title: From predicting myopia progression to identifying treatment benefit: interpreting choroidal remodeling during atropine therapy

Article References: Chen, J. (2026). From predicting myopia progression to identifying treatment benefit: interpreting choroidal remodeling during atropine therapy. Journal of Translational Medicine, 24(1), Article 1430. https://doi.org/10.1186/s12967-026-09224-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09224-5

Keywords: myopia progression, atropine therapy, choroidal remodeling, luminal volume, perifoveal luminal volume, AMIXT trial, MOSAIC trial, LAMP trial, intermittent exotropia, refractive progression, axial elongation, choroidal thickness, endothelial oxidative stress, nitric oxide signaling, mediation analysis, pediatric ophthalmology

News Source: Ophelia Keating. (November 17, 2026). Early Choroidal Changes Predict Myopia Progression but May Not Show Treatment Benefit. Scienmag.

Tags: AMIXT trialatropine therapyaxial elongationchoroidal remodelingchoroidal thicknessendothelial oxidative stressintermittent exotropiaLAMP trialluminal volumemediation analysisMOSAIC trialmyopia progressionNitric oxide signalingpediatric ophthalmologyperifoveal luminal volumerefractive progression
Share12Tweet7Share2ShareShareShare1

Related Posts

Survey Reveals Severe Staffing Shortages Constrain Korean Medicine Education Units

Survey Reveals Severe Staffing Shortages Constrain Korean Medicine Education Units

November 18, 2026
Review Examines Electrical Impedance Tomography Across 116 Pediatric and Neonatal Studies

Review Examines Electrical Impedance Tomography Across 116 Pediatric and Neonatal Studies

November 18, 2026

Criteria-Based Nanocarrier Selection May Aid Clinical Translation in Drug Delivery

November 18, 2026

Comorbidities and Walking Difficulty Associated With Lower Quality of Life in MOGAD

November 18, 2026

POPULAR NEWS

  • Neural Network Inverse Design Optimizes Broadband Hybrid Plasmonic Leaky Wave Antenna

    Neural Network Inverse Design Optimizes Broadband Hybrid Plasmonic Leaky Wave Antenna

    29 shares
    Share 12 Tweet 7
  • Livestock Holdings and Agroecology Shape Carnivore Conservation Attitudes in Southern Ethiopia

    29 shares
    Share 12 Tweet 7
  • Researchers Identify GRAM Genes Across Cultivated Sweetpotato and Two Diploid Relatives

    29 shares
    Share 12 Tweet 7
  • Sensor Weighted Crop Simulations Significantly Improve Drone Maize Leaf Area Retrieval

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Global Modeling Reveals Potential Health Gains of H. pylori Screening Strategies

Survey Reveals Severe Staffing Shortages Constrain Korean Medicine Education Units

Review Examines Electrical Impedance Tomography Across 116 Pediatric and Neonatal Studies

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.